Persistent Asset Partners’s AbbVie ABBV Stock Holding History

Persistent Asset Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,126	Closed	-$1.33M	–	806
2026 Q1	$1.33M	Buy	+6,126	New	+$1.36M	0.5%	50

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Persistent Asset Partners's ABBV Position: Q2 2026 in Review

Persistent Asset Partners sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 6,126 shares — an estimated $1.33M sold.

Persistent Asset Partners first reported a position in ABBV in Q1 2026 and held it in 1 quarter. The position peaked at $1.33M in Q1 2026. 4,207 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Persistent Asset Partners reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Persistent Asset Partners sold 6,126 AbbVie shares in Q2 2026, an estimated $1.33M.
Persistent Asset Partners first reported a position in AbbVie in Q1 2026 and held it in 1 quarter.
Persistent Asset Partners's AbbVie position peaked at $1.33M in Q1 2026.
4,207 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.